Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus tocilizumab in pediatric systemic juvenile idiopathic arthritis
NL-OMON59963Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of upadacitinib and tocilizumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by AbbVie Inc. Primary endpoint: Adapted sJIA ACR30 response at Week 12. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
upadacitinibtocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NL-OMON59963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59963.